Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 6/20 | 1.00 |
| ▸ | TPMT | P51580 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9644843 | 0.87 | GSK3B (0.76) | GSK3BCA1CA2PDPK1ALDH1A1 | |
| SCHEMBL5080169 | 0.84 | GSK3B (0.72) | GSK3BTPMTCA1CA2SLC6A2 | |
| SCHEMBL5757857 | 0.82 | GSK3B (0.69) | GSK3BTPMTCA1CA2SLC6A2 | |
| SCHEMBL2096724 | 0.78 | GSK3B (0.64) | GSK3BCA1CA2SLC6A2SLC6A4 | |
| SCHEMBL2962521 | 0.78 | GSK3B (0.64) | GSK3BTPMTCA1CA2ALDH1A1 | |
| SCHEMBL7350941 | 0.78 | GSK3B (0.64) | GSK3BCA1CA2PDPK1PTPN1 | |
| SCHEMBL24408904 | 0.76 | GSK3B (0.61) | GSK3BTPMTCA1CA2SLC6A2 | |
| SCHEMBL3364624 | 0.76 | GSK3B (0.61) | GSK3BCA1CA2SLC6A2SLC6A3 | |
| SCHEMBL3424507 | 0.76 | GSK3B (0.61) | GSK3BCA1CA2ALDH1A1 | |
| SCHEMBL5696515 | 0.76 | GSK3B (0.61) | GSK3BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6747057-B2 | SUCH 1-(2-BROMO-4,5-DICHLORO-THIOPHEN-3-YL)-2-CHLORO-ETHANONE FOR TREATMENT OF ALZHEIMER'S DISEASE OR DIABETES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2004-06-08 | — | — | US | disclosed |
| US-20030199508-A1 | Compounds and their therapeutic use | UNIVERSIDAD AUTONOMA DE MADRID (UAM) (ES) | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199508-A1 | Compounds and their therapeutic use | CNKSR1, CBR1, CBR3 | GSK3B 4/4885TPMT 2104/4885CA1 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.